Translational Research
Volume 156, Issue 3 , Pages 107-111 , September 2010

Advances and challenges in translating stem cell therapies for clinical diseases

  • Michael A. Matthay

      Affiliations

    • Corresponding Author InformationReprint requests: Michael A. Matthay, MD, Cardiovascular Research Institute, University of California San Francisco, 505 Parnassus Ave, M-917, San Francisco, CA 94143-0624

References 

  1. Alaiti MA, Ishikawa M, Costa MA. Bone marrow and circulating stem/progenitor cells for regenerative cardiovascular therapy. Trans Res. 2010;156:112–129
  2. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5:54–3
  3. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–6
  4. Lionetti V, Recchia FA. New therapies for the failing heart: trans-genes versus trans-cells. Trans Res. 2010;156:130–135
  5. Pino CJ, Humes HD. Stem cell technology for the treatment of acute and chronic renal failure. Trans Res. 2010;156:161–168
  6. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol. 2009;20:1053–1067
  7. Schwartz SC, Schwarz J. Translation of stem cell therapy for neurological diseases. Trans Res. 2010;156:155–160
  8. Shaker A, Ruben DC. Intestinal stem cells and epithelial-mesenchymal interactions in the crypt and stem cell niche. Trans Res. 2010;156:179–186
  9. Sueblinvong V, Weiss DJ. Stem cells and cell therapy approaches in lung biology and diseases. Trans Res. 2010;156:187–204
  10. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009;106:16357–16362
  11. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42–49
  12. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010;
  13. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007;104:11002–11007
  14. Dudek AZ. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Trans Res. 2010;156:136–146
  15. Knorr DA, Kaufman DS. Pluripotent stem cell-derived natural killer cells for cancer therapy. Trans Res. 2010;156:147–154
  16. Wagner RT, Lewis J, Cooney A, Chan L. Stem cell approaches for the treatment of type 1 diabetes mellitus. Trans Res. 2010;156:169–178

PII: S1931-5244(10)00155-6

doi: 10.1016/j.trsl.2010.07.007

Translational Research
Volume 156, Issue 3 , Pages 107-111 , September 2010

Article Tools